Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 8, Pages 1943-1949
Publisher
Springer Nature America, Inc
Online
2014-03-19
DOI
10.1038/bjc.2014.131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Longer operative time is associated with higher risk of severe complications after percutaneous nephrolithotomy: Analysis of 1511 cases from a Japanese nationwide database
- (2013) Toru Sugihara et al. INTERNATIONAL JOURNAL OF UROLOGY
- A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
- (2013) Yousuke Nakai et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis
- (2013) ChongLek Lee et al. MEDICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A nomogram predicting severe adverse events after ureteroscopic lithotripsy: 12 372 patients in a Japanese national series
- (2012) Toru Sugihara et al. BJU INTERNATIONAL
- A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
- (2012) Y Nakai et al. BRITISH JOURNAL OF CANCER
- Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1
- (2012) Yousuke Nakai et al. CANCER SCIENCE
- Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
- (2012) Chen Sun WORLD JOURNAL OF GASTROENTEROLOGY
- Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer
- (2011) R. Liu et al. CLINICAL CHEMISTRY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nomograms for staging, prognosis, and predicting treatment outcomes
- (2010) Karim Touijer et al. CANCER
- Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy
- (2010) Yousuke Nakai et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer
- (2010) Yousuke Nakai et al. PANCREAS
- How To Build and Interpret a Nomogram for Cancer Prognosis
- (2008) Alexia Iasonos et al. JOURNAL OF CLINICAL ONCOLOGY
- CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer
- (2008) Yousuke Nakai et al. ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started